

NIH Public Access

Author Manuscript

Org Lett. Author manuscript; available in PMC 2010 February 5

Published in final edited form as:

Org Lett. 2009 February 5; 11(3): 571-574. doi:10.1021/ol802675j.

Tandem Enyne Metathesis–Metallotropic [1,3]-Shift for a Concise Total Syntheses of (+)-Asperpentyn, (-)-Harveynone, and (-)-Tricholomenyn A

Jingwei Li, Sangho Park[†], Reagan L. Miller[‡], and Daesung Lee^{*}

Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, Illinois 60607

Abstract



A tandem reaction sequence involving relay metathesis-induced enyne RCM and metallotropic [1,3]shift is an effective tool to construct cyclic alkenes with embedded 1,5-dien-3-yne moieties from acyclic precursors containing a 1,3-diyne. Total syntheses of (+)-asperpentyn, (-)-harveynone and (-)-tricholomenyn A have been accomplished by implementing this metathesis-based tandem reaction sequence as the key step.

Epoxyquinoids, a subclass of naturally occurring cyclohexane epoxides, display a broad range of structural variation and impressive biological activities, and thus have elicited significant synthetic and biological studies.¹ Among many naturally occurring epoxyquinoids, (+)-asperpentyn,² (-)-harveynone³ and its prenylated homolog (-)-tricholomenyn A⁴ have an embedded 1,5-dien-3-yne moiety (Scheme 1). Due to this structural characteristic, Ogasawara, ⁵ Johnson,⁶ Taylor,⁷ Maycock,⁸ Negishi,⁹ and Kitahara¹⁰ utilized Pd-catalyzed Sonagashira or Stille coupling between the preformed 2-bromo- or iodocyclo-hexenone derivatives (bromoxone or its iodo analogue)¹¹ and appropriate 1,3-enyne counterparts for their total syntheses.

We envisioned a conceptually new strategy relying on enyne metathesis¹²-based construction of the cyclohexene core with concommitant installation of the 1,3-enyne moieties starting from the corresponding acyclic precursors. This new approach will harness a streamlined sequence of enyne ring-closing metathesis followed by metallotropic [1,3]-shift,¹³ whereby the 1,5-dien-3-yne moiety will be directly installed on the incipient epoxycyclohexene ring. Herein we describe a successful application of this powerful tandem reaction to the concise syntheses of (+)-asperpentyn, (-)-harveynone and (-)-tricholomenyn A.

dsunglee@uic.edu.

[†]Current Address: Samsung Electronics Co., LTD, San 14-1 Nongseo-Dong, Giheung-Gu, Yongin-City, Gyeonggi-Do, Korea 446-712. [‡]Current Address: Baxter Healthcare Corporation, 25212 W. Il-Rte 120 WG3-3S, Round Lake, IL 60073

Retrosynthetically, we envisaged that cyclohexene derivative 1 with an appropriate R substituent would serve as a common advanced intermediate for all three natural product targets: (+)-asperpentyn, (-)-harveynone and (-)-tricholomenyn A (Scheme 2). A direct precursor of 1 would be an acyclic 1,3-diyne-contaning compound 2 or its simpler variant lacking the relay device. The pivotal metathesis substrate 2 would be prepared through flouoride-catalyzed addition of silvlated 1,3-diyne 4 to epoxy aldehyde 3, which in turn would be derived from aldehyde 5^{14} and allyl propargyl ether 6. To test the feasibility of the key step, alkene-tethered 1.3-divne 11 was prepared from commercially available cis-2-buten-1.4-diol 7 in 8 steps (Scheme 3). Following the known procedure involving the Sharpless asymmetric epoxidation 15 , the diol 7 was elaborated to epoxide 8. Oxidation of the primary alcohol with PCC to generate aldehyde 5 was followed by addition of vinyl magnesium bromide, MOMprotection of the resultant secondary alcohol (1:1 mixture) and removal of the TBS group afforded primary alcohol 9. After Dess-Martin oxidation¹⁶ of the primary alcohol, a lithiated divide derived from 10 was added to provide RCM substrate 11. Disappointingly, however, treatment of 11 with Grubb's second-generation catalyst did not effect the ring closure to generate 12. We assumed that the initiation was hindered by the steric congestion around the vinyl group.¹⁷

To overcome this hindered initiation, a relay metathesis strategy was adopted, which entails the preparation of more elaborated RCM substrate 2 containing the relay device.¹⁸ Along this modified plan, the first goal is to synthesize a common intermediate that can branch off to different target molecules, which is aldehyde **16** (Scheme 4). The synthesis of **16** was commenced with the addition of acetylide derived form allyl propargyl ether **6** to an aldehyde derived from alcohol **8**, providing separable diastereomeric alcohols **13** and **14** in a 1:2 ratio. The desired β -epimer **13** was easily elaborated to acetate **15** via controlled partial hydrogenation¹⁹ (H₂, Pd/CaCO₃, Pb(OAc)₄, quinoline, Hexane/EtOAc 1:1) and acetylation (Ac₂O, pyr, DMSO, DCM). For a more practical material throughput, without separation the mixture of two epimers, **13** and **14** were subjected to a four-step sequence to convert to **15**, which involves Dess-Martin oxidation of the secondary alcohols, (*R*)-Me-CBS mediated reduction,²⁰ partial hydrogenation of the triple bond, and Mitsunobu reaction with acetic acid. ²¹ Removal of the TBS group from **15**, followed by oxidation of the corresponding primary alcohol gave the aldehyde **16**.

For the synthesis of asperpetyne and harveynone, aldehyde **16** was reacted with triethylsilyl-1,3-pentadiyne **17**²² and a catalytic amount of the anhydrous fluoride source tetrabutylammonium difluorotriphenylsilicate (TBAT),²³ providing enyne RCM substrate **18** after silyl concomitant protection of the secondary alcohol (Scheme 5). Treatmenent of **18** with Grubbs second-generation catalyst²⁴ in a dilute solution of CH₂Cl₂, a mixture of epimers **23** and **24** was isolated in 62% yield along with unidentified byproducts.

Based on the level of our understanding, we believe that the overall metathesis process started from the teminal alkene of the allyl ether relay device to form **19** initially, which then delivers the ruthenium moiety intramolecularly to the *cis*- alkene to generate a new propagating alkylidene **20**. Subsequent enyne RCM generating alkynyl Ru- alkylidene **21** would induce facile metallotropic [1,3]-shift to generate fully conjugated alkylidene **22**. The termination at the sterically less hindered carbon through **22** would ultimately deliver the final products **23** and **24**, thereby establishing 1,5-diene-3-yne substructure.¹³

After separation, the C1- β -epimer **23** was elaborated to (+)-asperpentyn through the removal of both the C1-TES group and C4-acetate in one step (KCN, EtOH 95%) (Scheme 6). Also, the TES-group on C1- β -epimer of **23** was selectively deprotected to generate alcohol **25** (HF·pyr, pyr, CH₂Cl₂, 0 °C), which was then oxidized to acetylated harveynone **26**. Unfortunately, under a variety of conditions, the C4-acetate of **26** could not be removed

Org Lett. Author manuscript; available in PMC 2010 February 5.

The total synthesis of (-)-tricholomenyn A was commenced with intermediate aldehyde **16** and triethylsilyl-1,3-diyne **31** (Scheme 7).²² 1,3-Diyne **31** was prepared via Colvin's rearrangement²⁵ from ketone **30**, which in turn can be readily prepared from known aldehyde **29**.²⁶ The reaction between aldehyde **16** and silyl-1,3-diyne **31** in the presence of a catalytic amount (5 mol %) of tetrabutylammonium difluorotriphenylsilicate (TBAT)²³ provided silylated adduct **32** (1:1 epimeric mixture), which was subjected to RCM to generate **33** as a separable mixture of epimers. The removal of the TES-protecting group from **33** (HF·pyr) followed by oxidation (MnO₂, CHCl₃) delivered the target natural product (-)-tricholomenyn A in good yield.

In summary, we have developed a novel strategy to synthesize epoxyquinone natural products bearing a 1,5-diene-3-yne moiety via a tandem sequence of relay metathesis-induced ringclosing enyne metathesis and metallotropic [1,3]-shift. By using this strategy, we have accomplished the total syntheses of (+)-asperpentyn, (-)-harveynone and (-)-tricholomenyn A. The scope and utility of this metathesis-based tandem bond-forming reaction will be further explored using other natural product targets.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the NIH (CA106673) for financial support of this work.

References

- Reviews: (a) Marco-Contelles J, Molina MT, Anjum S. Chem Rev 2004;104:2857. [PubMed: 15186183] (b) Shoji M, Hayashi Y. Eur J Org Chem 2007:3783. (c) Ogasawara K. J Synth Org Chem Jpn 1999;57:957.
- 2. Muhlenfeld A, Achenbach H. Phytochemistry 1988;27:3853.
- Nagata T, Ando Y, Hirota A. Biosci Biotechnol Biochem 1992;56:810. (b) Kawazu K, Kobayashi A, Oe K. Chem Abstr 1991;115:1815.JP 0341,075,1991
- 4. Garlaschelli L, Magistrali E, Vidari G, Zuffardi O. Tetrahedron Lett 1995;36:5633.
- 5. (a) Kamikubo T, Ogasawara K. Chem Commun 1996:1679. (b) Kamikubo T, Ogasawara K. Heterocycles 1998;47:69.
- 6. Miller MW, Johnson CR. J Org Chem 1997;62:1582.
- (a) Graham AE, McKerrecher D, Huw Davies D, Taylor RJK. Tetrahedron Lett 1996;37:7445. (b) Graham AE, Taylor RJK. J Chem Soc, Perkin Trans 1 1997:1087.
- 8. Barros MT, Maycock CD, Ventura MR. Chem Eur J 2000;6:3991.
- 9. Negishi, Ei; Tan, Z.; Liou, SY.; Liao, B. Tetrahedron 2000;56:10197.
- 10. Tachihara T, kitahara T. Tetrahedron 2003;59:1773.
- Synthesis of other epoxyquinoid natural products using bromoxone and its iodo analogs, see: (a) Moses JE, Commeiras L, Baldwin JK, Adlington RM. Org Lett 2003;5:2987. [PubMed: 12916962]
 (b) Block O, Klein G, Altenbach HJ, Brauer DJ. J Org Chem 2000;65:716. [PubMed: 10814002] (c) Li C, Pace EA, Liang MC, Lobkovsky E, Gilmore TD, Porco JA Jr. J Am Chem Soc 2001;123:11308.

Page 3

Org Lett. Author manuscript; available in PMC 2010 February 5.

[PubMed: 11697981] (d) Shotwell JB, Hu S, Medina M, Cole R, Crews CM, Wood JL. Tetrahedron Lett 2000;41:9639. (e) Porco JA Jr, Su S, Lei X, Bardhan S, Rychnovsky SD. Angew Chem Int Ed 2006;45:5790. (f) Lei X, Johnson RP, Porco JA Jr. Angew Chem Int Ed 2003;42:3913. (f) Shoji M, Yamaguchi J, Kakeya H, Osada H, Hayashi Y. Angew Chem Int Ed 2002;41:3191.

- For recent reviews on enyne metathesis, see: (a) Giessert AJ, Diver ST. Chem Rev 2004;104:1317. [PubMed: 15008625] (b) Poulsen CS, Madsen R. Synthesis 2003:1. (c) Mori M. Top Organomet Chem 1998;1:133.(d)MoriMHandbook of MetathesisGrubbsRHWiley-VCHWeinheim, Germany20032176204
- 13. (a) Kim M, Miller RL, Lee D. J Am Chem Soc 2005;127:12818. [PubMed: 16159273] (b) Cho EJ, Lee D. Org Lett 2008;10:257. [PubMed: 18076184]A review on metallotropic [1,3]-shift, (c) Kim M, Lee D. Org Biomol Chem 2007;5:3418. [PubMed: 17943198]
- 14. Paquette LA, Mitzel TM. J Am Chem Soc 1996;118:1931.
- (a) Cao Y, Hanson RM, Klunder JM, Ko SY, Masamune H, Sharpless KB. J Am Chem Soc 1987;109:5765. (b) Astles PC, Thomas EJ. J Chem Soc, Perkin Trans 1 1997:845.
- 16. Dess DB, Martin JC. J Org Chem 1983;48:4155.
- The effect of protecting group on allylic alcohol in ring-closing metathesis, see: Hoye TR, Zhao H. Org Lett 1999;1:1123. [PubMed: 10825965]
- 18. (a) Hoye TR, Jeffrey CS, Tennakoon MA, Wang J, Zhao H. J Am Chem Soc 2004;126:10210.
 [PubMed: 15315410] (b) Hansen EC, Lee D. Org Lett 2004;6:2035. [PubMed: 15176812]
- 19. A significant amount of overreduced product from hydrogenation of the terminal alkene was obtained when commercially available Lindlar catalyst without further poisoning was used.
- 20. Parker KA, Ledeboer MW. J Org Chem 1996;61:3214. [PubMed: 11667191]Several attempts had been carried out to optimize the asymmetric reduction. By using 2 equiv (S)-Me-CBS reagent, the ratio of α : β was increased slightly from 1:2 to 1:3, whereas higher stereoselectivity was observed when 2 equiv of (R)-Me-CBS was used, the α -isomer having the opposite stereochemistry at C4 was the major product and the ratio of α : β was up to 10:1.
- 21. Hughes DL, Reamer RA. J Org Chem 1996;61:2967. [PubMed: 11667155]
- 22. The preparation of TES-protected diyne **17** and **31** is described in the Supporting Information. For the compound **17**, see: Shakhovskoi BG, Petrov AA. Zhurnal Obshchei Khimii 1967;37:1371.
- (a) Pilcher AS, DeShong P. J Org Chem 1996;61:6901. [PubMed: 11667585] (b) Furman B, Dziedzic M. Tetrahedron Lett 2003;44:6629.
- 24. Scholl M, Ding S, Lee CW, Grubbs RH. Org Lett 1999;1:953. [PubMed: 10823227]
- (a) Colvin EW, Hamill BJ. J Chem Soc, Chem Commun 1973:151. (b) Miwa K, Aoyama T, Shioiri T. Synlett 1994:107. (c) Colvin EW. J Chem Soc, Perkin Trans 1 1977:869.
- 26. Kraus GA, Kim J. Org Lett 2004;6:3115. [PubMed: 15330601]









Retrosynthetic Analysis for the Total Syntheses of (+)-Asperpentyn, (-)-Harveynone, and (-)-Tricholomenyn.

NIH-PA Author Manuscript



Scheme 3. Model Study to Test the Enyne RCM



Scheme 4.



Scheme 5. Enyne RCM and Metallotropic [1,3]-Shift.

Org Lett. Author manuscript; available in PMC 2010 February 5.



Scheme 6. Completion of (+)-Asperpentyn and (-)-Harveynone.



Scheme 7. Completion of (-)-Tricholomenyn A.